Cargando…

A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale

AIM: Attenuated psychosis syndrome (APS), a condition for further study in the Diagnostic and Statistical Manual of Mental Disorders‐5, comprises psychotic symptoms that are qualitatively similar to those observed in schizophrenia but are less severe. Patients with APS are at high risk of converting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keefe, Richard S. E., Woods, Scott W., Cannon, Tyrone D., Ruhrmann, Stephan, Mathalon, Daniel H., McGuire, Philip, Rosenbrock, Holger, Daniels, Kristen, Cotton, Daniel, Roy, Dooti, Pollentier, Stephane, Sand, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451588/ https://www.ncbi.nlm.nih.gov/pubmed/33354862 http://dx.doi.org/10.1111/eip.13083

Ejemplares similares

Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders
por: Scarborough, Joseph, et al.
Publicado: (2021)

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia
por: Brown, David, et al.
Publicado: (2017)

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
por: Brown, David, et al.
Publicado: (2019)

The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study
por: Müller, Fabian, et al.
Publicado: (2022)

First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males
por: Moschetti, Viktoria, et al.
Publicado: (2016)

T116. PREDICTION OF REMISSION IN NON-CONVERTING INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS
por: Worthington, Michelle, et al.
Publicado: (2020)

39.1 DNA METHYLATION OF IMMUNE CELLS IN PERSONS AT CLINICAL HIGH RISK FOR PSYCHOSIS
por: Perkins, Diana, et al.
Publicado: (2018)

S184. MACHINE LEARNING REVEALS DEVIANCE IN NEUROANATOMICAL MATURITY PREDICTIVE OF FUTURE PSYCHOSIS IN YOUTH AT CLINICAL HIGH RISK
por: Chung, Yoonho, et al.
Publicado: (2018)

Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes
por: Deng, Wisteria, et al.
Publicado: (2023)

21.3 NEUROIMAGING MARKERS OF RISK FOR AND PROGRESSION TO FULL PSYCHOSIS IN THE NAPLS PROJECT
por: Cannon, Tyrone
Publicado: (2018)

Depression Predicts Global Functional Outcomes in Individuals at Clinical High Risk for Psychosis
por: Deng, Wisteria, et al.
Publicado: (2021)

O2.8. TRAJECTORIES OF NEUROCOGNITIVE FUNCTIONING OVER TIME IN YOUTH AT CLINICAL HIGH RISK WHO DO AND DO NOT TRANSITION TO PSYCHOSIS
por: Woodberry, Kristen, et al.
Publicado: (2018)

F32. DIFFERENCES BETWEEN YOUTH AT CLINICAL HIGH-RISK FOR PSYCHOSIS WHO DO NOT TRANSITION TO PSYCHOSIS: THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY (NAPLS-2)
por: Santesteban-Echarri, Olga, et al.
Publicado: (2018)

O9.8. STRESS AND COGNITIVE FUNCTION AMONG INDIVIDUALS AT CLINICAL HIGH-RISK FOR PSYCHOSIS: FINDINGS FROM THE NAPLS COHORT
por: Cullen, Alexis, et al.
Publicado: (2018)

Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis
por: Buchy, Lisa, et al.
Publicado: (2015)

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
por: Rosenbrock, Holger, et al.
Publicado: (2023)

The impact of early factors on persistent negative symptoms in youth at clinical high risk for psychosis
por: Devoe, Daniel J., et al.
Publicado: (2023)

Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort
por: Cullen, Alexis E., et al.
Publicado: (2020)

Discriminatory experiences predict neuroanatomical changes and anxiety among healthy individuals and those at clinical high risk for psychosis
por: Collins, Meghan A., et al.
Publicado: (2021)

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease
por: Frölich, Lutz, et al.
Publicado: (2019)

Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort
por: Chung, Yoonho, et al.
Publicado: (2019)

Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project
por: Perkins, Diana O., et al.
Publicado: (2015)

Theory of mind, emotion recognition and social perception in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort
por: Barbato, Mariapaola, et al.
Publicado: (2015)

O10.2. DEFICIENT VISUAL ODDBALL STIMULUS PROCESSING PREDICTS PSYCHOSIS ONSET: RESULTS FROM THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY
por: Hamilton, Holly, et al.
Publicado: (2020)

Neurobehavioral risk factors influence prevalence and severity of hazardous substance use in youth at genetic and clinical high risk for psychosis
por: Amir, Carolyn M., et al.
Publicado: (2023)

O3.2. BRAIN HYPERACTIVATION DURING MEMORY RETRIEVAL PRECEDES AND PREDICTS CONVERSION TO PSYCHOSIS IN INDIVIDUALS AT CLINICAL HIGH RISK
por: Cao, Hengyi, et al.
Publicado: (2018)

Prediction and Prevention in the Clinical High-Risk for Psychosis Paradigm: A Review of the Current Status and Recommendations for Future Directions of Inquiry
por: Worthington, Michelle A., et al.
Publicado: (2021)

The Mini-SIPS: development of a brief clinical structured interview guide to diagnosing DSM-5 Attenuated Psychosis Syndrome and training outcomes
por: Woods, Scott W., et al.
Publicado: (2022)

Disrupted Working Memory Circuitry in Adolescent Psychosis
por: Eckfeld, Ariel, et al.
Publicado: (2017)

M20. CYTOKINE LEVELS THROUGHOUT PREGNANCY AND RISK FOR PSYCHOSIS IN ADULT OFFSPRING: EARLY PREGNANCY MATTERS
por: Allswede, Dana, et al.
Publicado: (2020)

How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis?
por: Kempton, Matthew J., et al.
Publicado: (2015)

Negative Symptom Trajectories in Individuals at Clinical High Risk for Psychosis: Differences Based on Deficit Syndrome, Persistence, and Transition Status
por: Tran, Tanya, et al.
Publicado: (2023)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis
por: Merritt, Kate, et al.
Publicado: (2013)

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

F118. ARCHITECTURE OF PSYCHOSIS SYMPTOMS AND NEURAL PREDICTORS OF CONVERSION AMONG CLINICAL HIGH RISK INDIVIDUALS WITH AUTISM SPECTRUM DISORDER
por: Foss-Feig, Jennifer, et al.
Publicado: (2018)

24.2 NEUROCOGNITIVE PROFILES IN THE PRODROME TO PSYCHOSIS IN NAPLS-1
por: Velthorst, Eva, et al.
Publicado: (2018)

Deficient Suppression of Default Mode Regions during Working Memory in Individuals with Early Psychosis and at Clinical High-Risk for Psychosis
por: Fryer, Susanna L., et al.
Publicado: (2013)

Basic Disturbances of Information Processing in Psychosis Prediction
por: Bodatsch, Mitja, et al.
Publicado: (2013)

S81. METAMEMORY IMPAIRMENT ACROSS THE PSYCHOSIS TRAJECTORY: ASSOCIATIONS WITH SYMPTOM SEVERITY
por: Seabury, Rashina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7h1crpmlf92g1oev2vdnn8pau6